Biophytis : announces the appointment of Dr Manfred Horst as Business Development Office. Read the Press Release

Manfred Horst, Doctor of Medicine (Ludwig-Maximilians-Universität, Munich), PhD in allergology and an MBA graduate from INSEAD, is a seasoned pharmaceutical business development executive with more than 25 years of pharmaceutical industry experience in marketing, market access and health economics, that will benefit Biophytis' operations. His deep experience of strategic positions at Ciba- Geigy/Novartis, Mercur Value Health Gesundheitspartner (Allianz group) and Merck Sharp & Dohme respectively, is an asset that will greatly contribute to the success of Biophytis's partnering strategy.

Prior to joining Biophytis, Manfred Horst was Business Development Director Europe at Merck Sharp

& Dohme from 2004 to 2016, where he has been fully involved in searching, negotiating and managing partnerships on behalf of Merck Research Laboratories, successfully contributing to the development of the group. Notably he has been responsible for several of Merck's most significant recent deals.

Stanislas Veillet, CEO of BIOPHYTIS, said: "We are delighted to welcome Dr Manfred Horst in our management team where he will be in charge of the business development of Biophytis. His know-how and insider experience of licensing activities in the pharmaceutical industry will be a valuable asset in achieving our goals for industrial partnerships."

***

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS ; ISIN: FR0012816825).

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.